Skip to main content
. 2014 Nov 19;4(6):874–885.

Figure 3.

Figure 3

Correlation between serum level of Hsp90-beta and clinicopathologic factors of lung cancer patients. A. Increased serum level of Hsp90-beta in lung cancer patients than benign and normal control groups; B. Increased serum level of Hsp90-beta in SCLC than LSCC and LAC; C. Undifferentiated and poorly undifferentiated patients revealed up-regulated level of Hsp90-beta than moderate and well differentiation; D. Lymphatic invasion patients (N1-N3) revealed increased level of Hsp90-beta than non-lymphatic invasion; E. Patients of III-IV stage had higher Hsp90-beta value than both the I-II stage; F. Serum level of Hsp90-beta was not significant difference about pleural invasion. LAC, adenocarcinoma of the lung; LSCC, squamous cell carcinoma of the lung; SCLC, small cell lung cancer; N, node stage (TNM classification).